Centro De Inmunologia Molecular

Maura Lisett Rábade Chediak

Luis Enrique Fernández Molina

Circe Mesa Pardillo

Kalet León Monzón

Audry Fernández Gómez

Elias Antonio Gracia Medina

Tays Hernández García

Giselle Hevia Hernández

Vladimir Peña Sánchez

Lourdes Hernández De La Rosa

Camilo Rodríguez Rodríguez

Leslie Pérez Ruíz

Orlando Valdés Guerrero

Lena Aguiar García

Rydell Alvarez Arzola

María Caridad Rubio Hernández

Liliana Oliver Ríos

Anet Valdés Zayas

Idelmis Curbelo Haredia

The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.

Fusion proteins composed of an interleukin-2 mutein and type I interferon

The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.

Ganglioside GM3-containing nanoparticles as immunomodulators

Growing community of inventors

Havana, Cuba

Maura Lisett Rábade Chediak